Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-5222 bioequivalence study in healthy volunteers
NCT07046715Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Jul 2025
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA-5222 (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under the Curve from time zero to last measurable concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Jul 2025; status: completed.
02
Drugs
DA-5222
Beyond the preview
Go deeper on NCT07046715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046715.